Sugi Predict

Sugi Predict / Compounds / SCHEMBL2933595

SCHEMBL2933595

SCHEMBL2933595

OC1CC(COCc2ccccc2)CC1O

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.50
▸ AGTR2 P50052 1/20 0.49
▸ CTSL P07711 1/20 0.48
▸ CTSB P07858 1/20 0.48
▸ CTSK P43235 1/20 0.48
▸ PDE4D Q08499 1/20 0.45
▸ NAAA Q02083 1/20 0.44
▸ CA1 P00915 3/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ TAAR1 Q96RJ0 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ BUB1 O43683 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2933597 1.00 TSHR (0.50) TSHRAGTR2CTSLCTSBCTSK
SCHEMBL10476612 1.00 TSHR (0.50) TSHRAGTR2CTSLCTSBCTSK
SCHEMBL10279867 1.00 TSHR (0.50) TSHRAGTR2CTSLCTSBCTSK
SCHEMBL477463 0.89 TSHR (0.50) TSHRAGTR2CTSLCTSBCTSK
SCHEMBL477464 0.89 TSHR (0.50) TSHRAGTR2CTSLCTSBCTSK
SCHEMBL598878 0.89 TSHR (0.50) TSHRAGTR2CTSLCTSBCTSK
SCHEMBL15044991 0.86 CTSL (0.44) TSHRAGTR2CTSLCTSBCTSK
Methoxymethane SCHEMBL967074 0.84 CTSL (0.48) TSHRAGTR2CTSLCTSBCTSK
Methoxymethane SCHEMBL967072 0.84 CTSL (0.48) TSHRAGTR2CTSLCTSBCTSK
SCHEMBL600663 0.84 TSHR (0.48) TSHRAGTR2CTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4469095-A1 IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES Janssen Biotech, Inc. (US) 2024-12-04 — — EP disclosed
EP-4429718-A1 MACROCYCLIC COMPOUNDS AND DIAGNOSTIC USES THEREOF Janssen Biotech, Inc. (US) 2024-09-18 — — EP disclosed
CN-118613288-A Immunoconjugates comprising kallikrein-related peptidase 2 antigen binding domains and uses thereof 詹森生物科技公司 2024-09-06 — — CN disclosed
US-20240238461-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF JANSSEN BIOTECH, INC. 2024-07-18 — — US disclosed
US-20240238461-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF JANSSEN BIOTECH, INC. 2024-07-18 — — US disclosed
CN-118302204-A Macrocyclic compounds and diagnostic uses thereof 詹森生物科技公司 2024-07-05 — — CN disclosed
EP-4284446-A2 IMMUNOCONJUGATES COMPRISING KALLIKREIN RELATED PEPTIDASE 2 ANTIGEN BINDING DOMAINS AND THEIR USES Janssen Biotech, Inc. (US) 2023-12-06 — — EP disclosed
CN-116806159-A Immunoconjugates comprising kallikrein-related peptidase 2 antigen binding domains and uses thereof 詹森生物科技公司 2023-09-26 — — CN disclosed
EP-4243935-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Janssen Biotech, Inc. (US) 2023-09-20 — — EP disclosed
CN-116615194-A Macrocyclic compounds and methods of use thereof 詹森生物科技公司 2023-08-18 — — CN disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 — — US disclosed
US-7192968-B2 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-20 — — US disclosed
US-20060004009-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 — — US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 — — US disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 — — US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 — — US disclosed
US-20040122063-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-24 — — US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 — — EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 — — EP disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004009-A1 Ethylenediamine derivatives F2, ECE1, MLLT1 TSHR 1606/4885AGTR2 2019/4885CTSL 3622/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R TSHR 516/4885AGTR2 1375/4885CTSL 2437/4885
US-20080015215-A1 DIAMINE DERIVATIVES C9, C1S, C1R TSHR 516/4885AGTR2 1375/4885CTSL 2437/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R TSHR 516/4885AGTR2 1375/4885CTSL 2437/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R TSHR 516/4885AGTR2 1375/4885CTSL 2437/4885
US-20240238461-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF BDNF, CD47, MAG TSHR 1143/4885AGTR2 3324/4885CTSL 612/4885
US-20040122063-A1 Ethylenediamine derivatives ECE1, F2, ECE2 TSHR 1769/4885AGTR2 1497/4885CTSL 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.